CRC - Mirati Therapeutics and Zai Lab ink collaboration agreement for adagrasib in Greater China

Mirati Therapeutics (MRTX) and Zai Lab (ZLAB) have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China (mainland China, Hong Kong, Macau and Taiwan).Mirati will receive a $65M upfront payment, with the potential to receive up to an additional $273M in milestone payments.Under the terms of the agreement, Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China.Zai Lab will support accelerated enrollment in key global, registration-enabling clinical trials of the treatment in patients with cancer who have a KRASG12C mutation.Mirati is also eligible to receive high-teen- to low-twenties-percent tiered royalties based on annual net sales of adagrasib in Greater China.

For further details see:

Mirati Therapeutics and Zai Lab ink collaboration agreement for adagrasib in Greater China